NCT00183898 - Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 28, 2004

Primary Completion Date

February 4, 2013

Study Completion Date

December 28, 2019

Conditions

Gastric CancerEsophageal Cancer

Interventions

DRUG

oxaliplatin, capecitabine

cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.

Trial Locations (1)

90033

U.S.C./Norris Comprehensive Cancer Center, Los Angeles